Ionis Pharmaceuticals Inc (IONS) Receives a Hold from Stifel Nicolaus

By Jason Carr

In a report released yesterday, Stephen Willey from Stifel Nicolaus reiterated a Hold rating on Ionis Pharmaceuticals Inc (NASDAQ: IONS), with a price target of $48. The company’s shares closed yesterday at $43.65.

According to TipRanks.com, Willey is a 5-star analyst with an average return of 21.5% and a 50.7% success rate. Willey covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Lexicon Pharmaceuticals, and Akcea Therapeutics Inc.

Ionis Pharmaceuticals Inc has an analyst consensus of Hold, with a price target consensus of $47.67.

See today’s analyst top recommended stocks >>

The company has a one-year high of $65.51 and a one-year low of $39.07. Currently, Ionis Pharmaceuticals Inc has an average volume of 952.1K.

Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is neutral on the stock. Most recently, in May 2018, Joseph Wender, a Director at IONS sold 15,000 shares for a total of $679,614.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs.